CDK4 and Miyoshi myopathy: Another proof-of-concept supporting the anti-tumour activity of p16-mimicking molecules comes from a patent filed for novel CDK4/6 inhibitors for the treatment of malignant mesothelioma, where the authors showed that the new inhibitors are able to stop proliferation of three MM cell lines (namely MSTO-211, NCI-H2052, NCI-H28) in vitro with cytostatic activity in the micromolar range [11].